实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2014年
11期
16-17,20
,共3页
癌症患者%输乏白细胞红细胞%TNF-α%IL-10
癌癥患者%輸乏白細胞紅細胞%TNF-α%IL-10
암증환자%수핍백세포홍세포%TNF-α%IL-10
cancer patients%leukocyte-depleted blood transfusions%TNF-α%IL-10
目的：探讨癌症患者输血前后 TNF-α和IL-10的变化及其意义。方法选取23例癌症并贫血患者，用ELISA法分别测定患者输血（输乏白细胞红细胞）前1 d和输血后第1天和第5天的血清TNF-α和IL-10的含量。结果输血前1 d、输血后第1天和输血后第5天血清TNF-α含量分别为（1.42±0.48）、（2.55±0.84）和（5.11±1.22）μg·L－1，IL-10含量分别为（6.86±1.09）、（9.93±1.48）和（9.83±1.30）μg·L－1。 TNF-α含量输血前1 d、输血后第1天和输血后第5天比较差异有统计学意义（均P＜0.01）；IL-10含量输血前1 d、输血后第1天比较差异有统计学意义（P＜0.01）。结论癌症患者输乏白细胞红细胞后仍然存在免疫抑制现象，加强输血风险评估对临床有一定的帮助。
目的：探討癌癥患者輸血前後 TNF-α和IL-10的變化及其意義。方法選取23例癌癥併貧血患者，用ELISA法分彆測定患者輸血（輸乏白細胞紅細胞）前1 d和輸血後第1天和第5天的血清TNF-α和IL-10的含量。結果輸血前1 d、輸血後第1天和輸血後第5天血清TNF-α含量分彆為（1.42±0.48）、（2.55±0.84）和（5.11±1.22）μg·L－1，IL-10含量分彆為（6.86±1.09）、（9.93±1.48）和（9.83±1.30）μg·L－1。 TNF-α含量輸血前1 d、輸血後第1天和輸血後第5天比較差異有統計學意義（均P＜0.01）；IL-10含量輸血前1 d、輸血後第1天比較差異有統計學意義（P＜0.01）。結論癌癥患者輸乏白細胞紅細胞後仍然存在免疫抑製現象，加彊輸血風險評估對臨床有一定的幫助。
목적：탐토암증환자수혈전후 TNF-α화IL-10적변화급기의의。방법선취23례암증병빈혈환자，용ELISA법분별측정환자수혈（수핍백세포홍세포）전1 d화수혈후제1천화제5천적혈청TNF-α화IL-10적함량。결과수혈전1 d、수혈후제1천화수혈후제5천혈청TNF-α함량분별위（1.42±0.48）、（2.55±0.84）화（5.11±1.22）μg·L－1，IL-10함량분별위（6.86±1.09）、（9.93±1.48）화（9.83±1.30）μg·L－1。 TNF-α함량수혈전1 d、수혈후제1천화수혈후제5천비교차이유통계학의의（균P＜0.01）；IL-10함량수혈전1 d、수혈후제1천비교차이유통계학의의（P＜0.01）。결론암증환자수핍백세포홍세포후잉연존재면역억제현상，가강수혈풍험평고대림상유일정적방조。
Objective To investigate the changes in TNF-α and IL-10 before and after leukocyte-depleted blood transfusions in cancer patients and their clinical significance. Methods The serum concentrations of TNF-α and IL-10 were measured by ELISA on the day before leukocyte-depleted blood transfusions and on the first and fifth days after blood transfusions in 16 cancer patients with anemia. Results The concentrations of TNF-α and IL-10 were, respectively, (1.42 ±0.48)μg·L-1 and (6.86±1.09)μg·L-1 on the day before blood transfusions,(2.55±0.84)μg·L-1 and (9.93±1.48)μg·L-1 on the first day after blood transfusions, and (5.11±1.22)μg·L-1 and (9.83±1.30)μg·L-1 on the fifth day after blood transfusions. The differences in TNF-α concentrations were significant among the three days (P<0.01).The differences in IL-10 concentrations were significant between the day before blood transfusions and the first day after blood transfusions (P<0.01). Conclusion The immunosuppression is present in cancer patients transfused with leukocyte-depleted blood. The enhancement of risk assessment can provide appropriate assistance for clinical blood transfusions.
